News coverage about Mallinckrodt (NYSE:MNK) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mallinckrodt earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.7696771818748 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Active-Investors: Blog Exposure – Baxter International Acquires RECOTHROM and PREVELEAK from Mallinckrodt (finanznachrichten.de)
- Mallinckrodt Will Sell RECOTHROM® And PREVELEAK® To Baxter (finance.yahoo.com)
- Mother Alleges Biotech Firm Stole Data From Her Sick Children (finance.yahoo.com)
- Mallinckrodt PLC (MNK) Forecasted to Earn FY2017 Earnings of $7.20 Per Share (americanbankingnews.com)
Several equities analysts have issued reports on the company. Mizuho reissued a “neutral” rating and issued a $21.00 price target (down from $22.00) on shares of Mallinckrodt in a research note on Tuesday. Cantor Fitzgerald set a $42.00 price target on Mallinckrodt and gave the company a “buy” rating in a research note on Monday. Goldman Sachs Group reaffirmed a “hold” rating on shares of Mallinckrodt in a research report on Monday, January 1st. Wells Fargo & Co reaffirmed a “hold” rating on shares of Mallinckrodt in a research report on Monday, January 1st. Finally, Canaccord Genuity set a $24.00 target price on Mallinckrodt and gave the stock a “hold” rating in a research report on Sunday. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $44.99.
Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, November 7th. The company reported $1.97 EPS for the quarter, topping the consensus estimate of $1.80 by $0.17. Mallinckrodt had a return on equity of 14.79% and a net margin of 11.43%. The business had revenue of $793.90 million during the quarter, compared to the consensus estimate of $808.93 million. During the same quarter last year, the company earned $2.04 EPS. The firm’s revenue was down 10.5% compared to the same quarter last year. equities research analysts predict that Mallinckrodt will post 7.21 EPS for the current fiscal year.
In other news, VP Steven J. Romano acquired 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were bought at an average cost of $21.96 per share, with a total value of $43,920.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Dr Kneeland Youngblood acquired 4,560 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were purchased at an average cost of $21.94 per share, for a total transaction of $100,046.40. Following the completion of the acquisition, the director now owns 19,789 shares in the company, valued at approximately $434,170.66. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 30,460 shares of company stock worth $659,486. Insiders own 0.53% of the company’s stock.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.